More ASCO abstracts

There is an abstract for X-396 that included 30 patients (21 NSCLC and only 13 ALK+). Maximum tolerated dose not reached. Current maximum dosage was 250mg.

In the 6 ALK+ patients who received greater than or equal to 200mg, 82% had a partial response (greater than 30%) and 17% had stable disease. Median duration of treatment is 20+ weeks and the longest is 58+ weeks.

Adverse events included rash (36%), fatigue (30%), nausea and vomiting (27%) and edema 20%).

http://abstracts.asco.org/144/AbstView_144_134110.html

=========================================================

There is an abstract on TSR-011 an inhibitor of ALK and TRK.
23 patients (10 NSCLC INCLUDING 5 ALK+). Doses have escalated from 30mg to 480mg. Maximum tolerated dose has been defined at a fractionated 60mg daily, which achives a sufficient trough concentration.

Of 5 patients with ALK+ NCSLC 3 (all Crizotinib resistant) achieved partial response.

Stable disease was observed in papillary thyroid, pancreatic, and colorectal patients.

http://abstracts.asco.org/144/AbstView_144_134653.html

========================================================

There is an abstract for RXDX101 an inhibitor of TRK, ROS1, and ALK.

17 patients have been treated up to 1200mg/m2. Maximum tolerated dose has not been reached. Most common adverse events were paresthesias, nausea, dysgeusia, and diarrhea. No DLTs seen to date.

A patient with neuroblastoma (ALK+) had a partial response and is in cycle 13. Two patients had prolonged stabilization of disease and remain on treatment including a (ALK+ NSCLC PATIENT) in cycle 11.

http://abstracts.asco.org/144/AbstView_144_131059.html

This entry was posted in Brain metastases, Lung cancer, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery. Bookmark the permalink.

Leave a Reply